Pyrotinib Active Not Recruiting Phase 3 Trials for HER2/Neu-positive Breast Cancer Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03588091Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer